LakeShore Biopharma Co., Ltd (LSBCF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LakeShore Biopharma Co., Ltd (LSBCF) has a cash flow conversion efficiency ratio of -0.001x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-693.96K) by net assets ($1.27 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is LakeShore Biopharma Co., Ltd worth for the company's overall valuation and market capitalisation.
LakeShore Biopharma Co., Ltd - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how LakeShore Biopharma Co., Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
LakeShore Biopharma Co., Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LakeShore Biopharma Co., Ltd ranked by their cash flow conversion efficiency. Explore LSBCF cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arkadia Digital Media Tbk PT
JK:DIGI
|
0.084x |
|
Vertical Explorations Inc
V:VERT
|
-0.001x |
|
District Copper Corp
V:DCOP
|
-0.238x |
|
Infinity Mining Ltd
AU:IMI
|
-0.021x |
|
Emetals Ltd
AU:EMT
|
-0.080x |
|
Tlou Energy Ltd
AU:TOU
|
-1.918x |
|
Unity Biotechnology Inc
NASDAQ:UBX
|
31.010x |
|
Pensana Rare Earths Plc
LSE:PRE
|
-0.065x |
Annual Cash Flow Conversion Efficiency for LakeShore Biopharma Co., Ltd (2021–2025)
The table below shows the annual cash flow conversion efficiency of LakeShore Biopharma Co., Ltd from 2021 to 2025. View LakeShore Biopharma Co., Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $499.75 Million | $-120.98 Million | -0.242x | +52.01% |
| 2024-03-31 | $585.21 Million | $-295.23 Million | -0.504x | -101.40% |
| 2023-03-31 | $728.45 Million | $-182.47 Million | -0.250x | +73.92% |
| 2022-03-31 | $180.68 Million | $-173.55 Million | -0.961x | +99.99% |
| 2021-03-31 | $21.36K | $-246.61 Million | -11543.271x | -- |
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS… Read more